Cencora, Inc.
COR
Positions held
Your positionsCOR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Cencora, Inc. operates in the medical distribution industry, which is experiencing steady growth due to increasing healthcare demands and an aging population.
- Revenue increased by 8% compared to the prior quarter, reaching $84.8 billion.
- The company has a strong buy recommendation with a score of 32.00, indicating positive market sentiment.
- The high debt-to-equity ratio of 446.516 raises concerns about financial stability and risk management.
- Gross margin decreased to 4.3% from 4.6% in the prior quarter, indicating potential challenges in maintaining profitability.
- Operating margin has been fluctuating, with a decline to 1.42% in the latest quarter from 1.74% in the previous quarter.
Fundamentals
| Market cap | $61.32B | Enterprise value | $73.16B | Trailing P/E | 23.86 | Forward P/E | 16.23 |
| PEG | 0.66 | Price / book | 20.10 | Beta | 0.58 | Dividend yield | 0.75% |
| Revenue growth | 5.1% | Earnings growth | 11.9% | Gross margin | 4.0% | Operating margin | 1.4% |
| Profit margin | 0.8% | ROE | 96.9% | ROA | 3.6% | Debt / equity | 4.47 |
| Current ratio | 0.94 | Free cash flow | $2.04B | Analyst recommendation | buy | Mean target | $369.92 |
| 52w high | $377.54 | 52w low | $244.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $84.8B | $78.4B | $85.9B | $83.7B | $80.7B | — |
| Op margin | 1.4% | 1.7% | 1.2% | 1.1% | 1.2% | — |
| Net income | $764M | $1.6B | $560M | -$340M | $687M | — |
| Gross margin | 4.3% | 4.6% | 3.6% | 3.5% | 3.6% | — |
| Gross profit | $3.6B | $3.6B | $3.1B | $3.0B | $2.9B | — |
| Operating income | $1.2B | $1.4B | $1.0B | $946M | $980M | — |
- Revenue +8% vs prior quarter ($84.8B vs $78.4B).
- Gross margin 4.3% (was 4.6% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $321.3B | $294.0B | $262.2B | $238.6B |
| Op margin | 1.2% | 1.1% | 1.0% | 1.2% |
| Net income | $1.6B | $1.5B | $1.7B | $1.7B |
| Gross margin | 3.6% | 3.4% | 3.4% | 3.5% |
| Gross profit | $11.5B | $9.9B | $9.0B | $8.3B |
| Operating income | $3.9B | $3.2B | $2.7B | $2.8B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Leerink Partners Adjusts Price Target on Cencora to $388 From $380
2026-10-06 · Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-05 · Cencora Insider Sold Shares Worth $298,935, According to a Recent SEC Filing
2026-10-04 · Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
2026-10-02 · Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
2026-10-02 · 2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
2026-10-01 · AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-28 · 1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down
2026-09-25 · AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
2026-09-25 · Cencora Elects Ryder Systems' Robert Sanchez to Board
2026-09-25 · Cencora Elects Robert E. Sanchez to Its Board of Directors
2026-09-24 · AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Price (daily)
Full chart · RSI · MACD · patterns